ImmunoPrecise Antibodies (IPA) has entered a strategic partnership with Ribopro to transform therapeutic antibody discovery and development.
The partnership will combine the mRNA [messenger ribonucliec acid]-based antigen expression expertise of Ribopro with the in silico and wet-lab antibody discovery capabilities of IPA.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Utilising Ribopro’s mRNA sequence optimisation and lipid nanoparticle-based delivery expertise alongside IPA’s single-cell analysis, B-cell screening and deep-learning AI-powered discovery workflows, the partnership focuses on expediting and improving the development of therapeutics by antigen presentation improvement and immune responses enhancement.
The use of Ribopro’s mRNA and lipid-based nanoparticle technologies within the collaboration allows for efficient antigen expression, potentially leading to immune responses and strengthening the path to discovering new antibody therapeutics.
IPA’s strategy melds AI-driven analytics with specialised wet-lab methodologies to design and optimise antibodies with clinical relevance.
ImmunoPrecise Antibodies chief scientific officer Dr Ilse Roodink stated: “We are enthusiastic to expand our toolbox for the discovery of novel therapeutic antibodies with a state-of-the-art mRNA immunisation platform in this alliance.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Combining Ribopro’s and IPA’s unique expertise further strengthens our commitment to be at the forefront of solving complex challenges with innovative and high-quality solutions.”
Based in the Netherlands and founded in 2020, Ribopro is a technology and service provider focusing on the development and manufacture of mRNA and LNPs.
Through subsidiaries such as BioStrand, ImmunoPrecise Antibodies in Canada and Europe, and Talem Therapeutics, IPA offers a solution for developing antibody therapeutics.
By integrating multi-omics modelling, systems biology and AI, IPA allows for the discovery of fully human therapeutic antibodies for complex disease targets.
